论文部分内容阅读
1 材料与方法 1.1 病例选择 从住院CHB患者中选择血清HGV-RNA阳性26例;HGV-RNA阴性52例,所有患者诊断分型均依照1995年5月北京第5次全国传染病与寄生虫病学术会议修定的病毒性肝炎防治方案,其血清HBsAg、HBeAg、HBV-DNA均阳性,ALT异常,并经肝穿活检病理证实(G_2～G_3)。HGV-RNA阳性与阴性两组患者在年龄、性别、病程、肝脏损害等方面差异均无显著性,具有可比性。 1.2 治疗方法 所有患者均予抗乙肝胎盘肽4ml,肌注,每日1次及维生素B_1、维生素C等药物口服,疗程4个月。抗乙肝胎盘肽由泰安东岳生物制药厂提供。 1.3 观察指标 全部病例治疗前后按常规方法检测血清ALT,按ELISA法检测血清HBsAg、抗-HBs、HBeAg、抗-HBe、抗-HBc-IgM,按PCR法及RT-PCR法检测血清HBV-DNA、
1 Materials and Methods 1.1 Case Selection Serum HGV-RNA was selected from hospitalized CHB patients 26 cases were positive; HGV-RNA-negative in 52 cases, all patients in accordance with the diagnostic typing in May 1995 Beijing 5th National Infectious and Parasitic Diseases The program of prevention and treatment of viral hepatitis revised by the academic conference was positive for serum HBsAg, HBeAg and HBV-DNA, and abnormal in ALT. It was confirmed by pathological examination of liver biopsies (G_2-G_3). HGV-RNA positive and negative groups of patients in terms of age, gender, duration of disease, liver damage and other differences were not significant, comparable. 1.2 Treatment All patients were anti-hepatitis B placental peptide 4ml, intramuscular injection, 1 day and vitamin B_1, vitamin C and other drugs, oral, treatment for 4 months. Anti-hepatitis B placental peptide from Taian Dongyue Biological Pharmaceutical Factory. 1.3 Observation Index All cases before and after treatment by routine detection of serum ALT, ELISA detection of serum HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc IgM by PCR and RT-PCR detection of serum HBV DNA ,